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The problem of identifying diﬀerential activity such as in gene expression is a major defeat in biostatistics and bioinformatics. Equally
important, however much less frequently studied, is the question of similar activity from one biological condition to another. The fold-
change, or ratio, is usually considered a relevant criterion for stating diﬀerence and similarity between measurements. Importantly, no
statistical method for concomitant evaluation of similarity and distinctness currently exists for biological applications. Modern micro-
array, digital PCR (dPCR), and Next-Generation Sequencing (NGS) technologies frequently provide a means of coeﬃcient of variation
estimation for individual measurements. Using fold-change, and by making the assumption that measurements are normally distributed
with known variances, we designed a novel statistical test that allows us to detect concomitantly, thus using the same formalism, diﬀer-
entially and similarly expressed genes (http://cds.ihes.fr). Given two sets of gene measurements in diﬀerent biological conditions, the
probabilities of making type I and type II errors in stating that a gene is diﬀerentially or similarly expressed from one condition to
the other can be calculated. Furthermore, a conﬁdence interval for the fold-change can be delineated. Finally, we demonstrate that
the assumption of normality can be relaxed to consider arbitrary distributions numerically. The Concomitant evaluation of Distinctness
and Similarity (CDS) statistical test correctly estimates similarities and diﬀerences between measurements of gene expression. The imple-
mentation, being time and memory eﬃcient, allows the use of the CDS test in high-throughput data analysis such as microarray, dPCR,
and NGS experiments. Importantly, the CDS test can be applied to the comparison of single measurements (N = 1) provided the var-
iance (or coeﬃcient of variation) of the signals is known, making CDS a valuable tool also in biomedical analysis where typically a single
measurement per subject is available.
Keywords: Statistical test; Fold-change; Distinctness; Similarity; Gene expression; Single measurement; Patient studyIntroduction
The problem of identifying diﬀerentially expressed genes
has been widely studied [1]. Considering two diﬀerent bio-
logical conditions, one aims to decide which genes are dif-
ferentially expressed from one biological condition to the1672-0229/$ - see front matter  2012 Beijing Institute of Genomics, Chinese A
Ltd and Science Press. All rights reserved.
http://dx.doi.org/10.1016/j.gpb.2012.06.002
⇑ Corresponding author.
E-mail: arndt@ihesfr (Benecke A).other, each composed of one or several gene expression
measurements. RNA quantiﬁcation, which is being used
in transcriptome analysis here will serve as an instance rep-
resentative of any type of high-throughput quantiﬁcation
of cellular components such as DNA, RNA, protein, or
metabolites, as the underlying problem of identifying sta-
tistically signiﬁcant changes remains similar independent
of the nature of the experiment. Therefore, all of what fol-
lows similarly applies to proteome or other measurements.cademy of Sciences and Genetics Society of China. Published by Elsevier
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Figure 1 Graphical representation of the problematic and encountered
scenarios
A. Expression signals of a single gene in two diﬀerent biological
conditions, with normal distributions having the parameters x1 and x2
(mean values) and r1 and r2 (variances). The fold-change criteria deﬁning
the diﬀerence or similarly is represented with a conic section deﬁned by
parameter h. The problem is to determine the value of (x1,x2) having the
values of estimators ð bx1 ; bx2Þ. B. Potential scenario for the statistical test for
diﬀerential expression and low variability. C. Potential scenario of having
low variability and similarly expressed genes. D. Potential scenario for the
statistical test for no statistical signiﬁcance and high variabilities.
128 Genomics Proteomics Bioinformatics 10 (2012) 127–135For the sake of simplicity, we will only continue to discuss
the case of gene expression investigations. First attempts to
tackle the question of diﬀerential quantities did not involve
statistics and genes having expression levels diﬀering by
more than an arbitrary cut-oﬀ fold-change value were con-
sidered to be diﬀerentially expressed [2,3]. Although the
identiﬁcation of statistically diﬀerentially expressed genes
has been widely covered [1], the identiﬁcation of similarly
expressed genes has been far less studied. This is surprising,
for several reasons. (i) Statistical measures for similarity
are an important tool in establishing reproducibility and
thus track technical and biological variation. (ii) In relative
quantiﬁcation, such as microarray experiments, where no
absolute numbers of, e.g., transcripts is established, a deﬁn-
ing procedure for what is considered similar, or unchanged,
expression would in turn also provide a sound basis for
deﬁning what is to be considered diﬀerent. (iii) Finally,
especially in the case of biomedical studies on human sub-
jects and patients, the question of genes with conserved
expression across diﬀerent biological conditions is of simi-
lar importance to the one of change [4].
When reasoning in a statistical manner, assumptions can
generally be made that gene expression measurements are
normally distributed. The simplest statistical method for
detecting diﬀerentially expressed genes is the two-sample
t-test [5]. The two-sample t-test allows us to formulate
statements concerning the diﬀerence between the means
of two normally distributed variables with the assumption
that the variances are unknown. On the other hand, the
two-sample z-test allows us to formulate statements con-
cerning the diﬀerence between the means of two normally
distributed variables with the assumption that the vari-
ances are known. However as this assumption can only
be made with a large sample of independent records or with
additional information about the variances, the two-sam-
ple t-test is more often used in the identiﬁcation of diﬀeren-
tially expressed genes. Diﬀerent variants of the two-sample
t-test can be classiﬁed in two groups: (i) methods such as
the two-sample t-test with relative thresholds [6] carrying
out local adjustments to account for biologically meaning-
ful diﬀerences, and the Signiﬁcance Analysis of Micro-
arrays method [7] that uses a gene-speciﬁc correction; and
(ii) jointly global and local methods such as the B-statistic
[8] and the regularized two-sample t-test [9]. In addition to
simple fold-change or t-test-like methods, another
approach is to consider the statistical properties of the ratio
of means of the two biological conditions sampled. Based
on the previous work [10], Chapman [11] proposed for
the ﬁrst time a statistical test in this direction. Recent meth-
ods (e.g., [12,13]) extended this approach by considering
conﬁdence intervals for the statistic of the ratio of the
two means used in hypothesis testing. When comparing dif-
ferent methods for diﬀerential expression detection, among
the desirable characteristics that a method should have are
reproducibility and control of type I and type II errors. Not
all of the existing methods necessarily combine both char-
acteristics [14]. Another way of comparing diﬀerent meth-ods is to measure their false positive and false negative
rates [15].
Assume two sets of gene expression measurements
obtained from two diﬀerent biological conditions (Figure 1).
By initially making the assumptions that the gene measure-
ments are normally distributed with known variances, we
represent the fold-change as the tangent of h in Figure 1A.
Having two biological conditions we can expect diﬀerent
scenarios. If both biological conditions have a small vari-
ance within biological replicates and then show diﬀerential
expression, then methods should detect them as signiﬁ-
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ally, the same metric would provide for detecting similar
expression across biological conditions (Figure 1C) when
they present small variability. However, when variability
is high, methods should indicate no statistical signiﬁcance
neither for similarity nor for diﬀerence (Figure 1D).
We describe here a statistical test, CDS for Concomitant
identiﬁcation of Distinctness and Similarity, which allows:
(i) obtaining statements on the fold-change rather than on
the diﬀerence between the mean expression levels; (ii) pro-
viding an estimate of the variance together with the signal;
(iii) obtaining bounds on the fold-change, both in case of
diﬀerentially expressed genes and similarly expressed genes.
CDS can thereby be used for single measurements of bio-
logical conditions (N = 1), provided an estimate of the var-
iance is available.Statistical approach
Test formulation
Let X be a random variable following the given distribution
Dx with unknown parameter x, and let x^ be an estimator of
the parameter x from a sample of independent observa-
tions of X. Let H0 be a null hypothesis and HA an alterna-
tive hypothesis, and let R0 and RA be two regions (we use
the term region as a synonym of set), such as:H 0 : x 2 R0
HA : x 2 RALet bR0 be the rejection region of H0 such that H0 is
rejected if and only if (iﬀ) x^ 2 bR0, and let bRA be the rejection
region of HA such that HA is rejected iﬀ x^ 2 R^A.
The probability of type I error, which is the probability
of making an error of rejecting the null hypothesisH0 when
it is actually true, is then deﬁned by:ProbðH 0 rejectedjH 0 trueÞ () Probðx^ 2 bR0jx 2 R0Þ
The probability of type II error, which is the probability
of making an error of rejecting the alternative hypothesis
HA when it is actually true, is then deﬁned by:ProbðHA rejectedjHA trueÞ () Probðx^ 2 bRAjx 2 RAÞ
For any regions ðR; bRÞ 2 fðR0; bR0Þ; ðRA; bRAÞg, it can be
noticed that we have:Probðx^ 2 bRjx 2 RÞ ¼ sup
x2R
Probðx^ 2 bRjxÞ
In plain words, Probðx^ 2 bRjx 2 RÞ is the probability that
the estimated value belongs to bR knowing that the actual
value of the parameter is x. Controlling
sup
x2R0
ProbðX 2 bR0jxÞ and sup
x2RA
ProbðX 2 bRAjxÞ is hence equiv-
alent to control probabilities of making type I and type II
errors in worst cases.Let Q0 and QA be these two probabilities such as:Q0ðR0; bR0Þ ¼ sup
x2R0
Probðx^ 2 bR0jxÞ ð1Þ
QAðRA; bRAÞ ¼ sup
x2RA
Probðx^ 2 bRAjxÞ ð2ÞThe above deﬁnitions can be exploited in three diﬀerent
ways. First, given regions R0 and RA deﬁned by a null
hypothesis H0 and an alternative hypothesis HA, and given
the estimator x^ deﬁning rejection regions bR0 and bRA such
that x^ 2 bR0 \ bRA, the probabilities of making type I and
II errors can be calculated (more precisely, upper bounded)
using Eqs. (1) and (2). Second, given the estimator x^ deﬁn-
ing rejection regions bR0 and bRA such that x^ 2 bR0 \ bRA and
given a conﬁdence level a, a conﬁdence interval for x can be
obtained by delimiting regions R0 and RA such that
Q0ðR0; bR0Þ ¼ QAðRA; bRAÞ ¼ a. Then, it will be stated with
a conﬁdence level a that x 2 ðR0 [ RAÞc (complement of
R0 [ RA). Third, given regions R0 and RA deﬁned by a null
hypothesis H0 and an alternative hypothesis HA, and given
e a maximal tolerance for probability of making type I and
type II errors, rejection regions bR0 and bRA can be delimited
such that Q0ðR0; bR0Þ ¼ QAðRA; bRAÞ ¼ . Then, H0 will be
rejected iﬀ x^ 2 bR0, and HA will be rejected iﬀ x^ 2 bRA, with
at most a probability e of making an error.
Formulation of fold-change statements
Let X1 be a random variable following a normal distribu-
tion X 1 :Nðx1; r21Þ and X 2 :Nðx2; r22Þ with
covðX 1;X 2Þ ¼ 0. Let s1 be a sample from X1 of size n1
and empirical meandxobs1 , and s2 be a sample from X2 of size
n2 and empirical mean
dxobs2 . Furthermore, assume that r1 is
known, and r2 is known (we will discuss this aspect later in
detail). Consider the samples s1 and s2 as two sets of expres-
sion measurements of a speciﬁc gene of interest in two dif-
ferent biological conditions. Formulating statistical
statements about the fold-change between the means x1
and x2 using the above described statistical approach leads
to adequately deﬁne regions R0, RA, bR0 and bRA. In order to
formulate fold-change statements between the means x1
and x2 of the two normal distributions, regions R0, RA,bR0 and bRA have to be deﬁned using conic sections Ch such
as:
Ch ¼ ða; bÞ 2 R2; tan p
4
 h
 
<
a
b
< tan
p
4
þ h
 n o
where 0  h  p
4
is an angle on each side of the ﬁrst
diagonal.
Moreover, means x1 and x2 must be controlled to avoid
a negative contribution of the distributions to the fold-
change. As only positive values of means have to be taken
into account, regions R0 and RA must be curtailed from
zero, and regions bR0 and bRA must be curtailed from bxobs1
and bxobs2 . We will henceforth alleviate the notations and
130 Genomics Proteomics Bioinformatics 10 (2012) 127–135use bx1ðresp: x^2Þ for the value x^obs1 (resp. x^obs2 ) of the estima-
tor of the mean x1ðresp:x2Þ, as computed from the data
sample.
Then, regions R0, RA, bR0, and bRA are deﬁned such as:
R0ðh0Þ ¼ ða; bÞ 2 R2; ða; bÞ 2 Ch0 and 0 < a and 0 < b
 
RAðhAÞ ¼ ða; bÞ 2 R2; ða; bÞ R ChA and 0 < a and 0 < b
 
bR0ðbh0; bx1;bx2Þ
¼ ða; bÞ 2 R2; ða; bÞ R Cbh0 and bx1 < a and bx2 < b
n o
bRAðbhA; bx1;bx2Þ
¼ ða; bÞ 2 R2; ða; bÞ 2 CbhA and bx1 < a and bx2 < b
n o
Figure 2 illustrates the deﬁnition of regions R0 (Fig-
ure 2A), RA (Figure 2B), bR0 (Figure 2C), and bRA (Fig-
ure 2D) with arbitrary parameters.
Probabilities Q0 and QA described in Eqs. (1) and (2)
with the above deﬁned regions are then deﬁned by:A B
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Figure 2 Representation of the diﬀerent regions R0, RA, bR0 and bRA
A. Region R0 shown in blue with h0 ¼ arctanð2Þ  p4. B. Region RA showbh0 ¼ arctanð2Þ  p4, bx1 ¼ 2 and bx2 ¼ 4. D. Region bRA shown in red with chA ¼Q0ðR0ðh0Þ; bR0ðbh0; bx1;bx2ÞÞ ¼ sup
ðx1;x2Þ2R0ðh0Þ
ProbððY 1; Y 2Þ
2 bR0ðbh0; bx1;bx2jx1; x2ÞÞ ð3Þ
QAðRAðhAÞ; bRAðbhA;bx1; bx2ÞÞ ¼ sup
ðx1;x2Þ2RAðhAÞ
ProbððY 1; Y 2Þ
2 bRAðbhA; bx1;bx2jx1; x2ÞÞ ð4Þ
with Y 1 :N x1; r21 ¼ r
2
1
n1
 
, Y 2 :N x2; r22 ¼ r
2
2
n2
 
, and
covðY 1; Y 2Þ ¼ 0.
As explained above, the above deﬁnitions can be
exploited in three diﬀerent ways. First, given two angles
h0 and hA that are relevant to assess the similarity and
the distinctness between x1 and x2, and given bx1 and bx2
deﬁning the rejection regions such as bR0ðh^; bx1;bx2Þ andbRAðh^; bx1;bx2Þ with h^ ¼ jarctanðbx2bx1Þ  p4 j, the probabilities of
making type I and II errors can be calculated using Eqs.
(3) and (4). To formulate fold-change statements, angles
h0 and hA are deﬁned as h0 ¼ arctanðfC0Þ  p4 andθΑ
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n in blue with hA ¼ arctanð2Þ  p4. C. Region bR0 shown in red with
arctanð2Þ  p
4
, bx1 ¼ 2 and bx2 ¼ 4.
Tchitchek N et al / Statistical Test to Identify Distinctness and Similarity Concomitantly 131hA ¼ arctanðfCAÞ  p4 where fC0 P 1 and fCA P 1 are two
fold-change values that are relevant to assess the similarity
and the distinctness between x1 and x2. Q0 (resp. QA) will
then give the probability of making an error when stating
that two genes are diﬀerentially (resp. similarly) expressed.
Second, given bx1 and bx2 (computed from the data samples)
deﬁning the rejection regions such as cR0ðh^; bx1 ; bx2Þ andcRAðh^; bx1 ; bx2Þ with h^ ¼ arctan bx2bx1
 
 p
4
 , and given a conﬁ-
dence level a, a conﬁdence interval for
h ¼ arctan x2x1
 
 p
4
  can be obtained by delimiting regions
R0(h0) and RA(hA) such that
Q0ðR0ðh0Þ;cR0ðchA ; bx1 ; bx2ÞÞ ¼ QAðRAðhAÞ;cRAðchA ; bx1 ; bx2ÞÞ ¼ a.
Then, it will be stated with a conﬁdence level a that
h 2 ðR0ðh0Þ [ RAðhAÞÞc which corresponds to the state that
h0 < h < hA. By denoting fC the fold-change between x1
and x2, this is equivalent to state with a conﬁdence level
a that fC0 < f C < f CA where fC0 ¼ tanðh0Þ þ p4,
fC ¼ tanðhÞ þ p4, and fCA ¼ tanðhAÞ þ p4. Third, given two
angles h0 and hA (i.e., fold-changes, see above) that are rel-
evant to assess the similarity and the distinctness between
x1 and x2, and given e a maximal tolerance for the proba-
bility of making type I and type II errors, rejection regionscR0ð bh0 ; bx1 ; bx2Þ and cRAðchA ; bx1 ; bx2Þ can be delimited. However,
as those regions are deﬁned by three parameters, their
delimitation is more complicated to deﬁne than for the
regions R0 and RA. Also, as they are not essential for our
question, we will not focus here on their delimitation.Test behavior and biological application
Test behavior
Let us have three diﬀerent situations as displayed in Figure 3
represented as bar charts: a gene showing statistically signif-
icantly diﬀerential expressions (Figure 3A), another gene
whose expression does not diﬀer statistically signiﬁcantly
from one to another condition (Figure 3B), and ﬁnally a sit-
uation where a given gene cannot be said to be statistically
signiﬁcantly diﬀerentially nor similarly expressed due to the
variability of its expression levels (Figure 3C).
As previously explained, Q0 is the probability of making
an error in stating that a certain gene is diﬀerentially
expressed between the two biological conditions. Lower
values (close to zero) of Q0 indicate then dissimilarities in
terms of gene expression as in Figure 3A (Q0 = 0.01) as
opposed to the cases presented in Figure 3B and C. Simi-
larly, QA is the probability of making an error in stating
that a certain gene is similarly expressed between the two
biological conditions. The situation displayed in Figure 3B
(QA = 0.03) can be considered as statistically signiﬁcant as
opposed to the cases presented in Figure 3A and C. More-
over, values such as the ones in the example of Figure 3C
are associated neither with similarity nor distinctness from
a statistical point of view.In summary, our examples suggest three typical situa-
tions when comparing the expression levels of a certain
gene between two diﬀerent biological conditions that our
statistical test can detect.
Biological application
In order to illustrate the behavior of our statistical test in a
biological application, we use a dataset coming from tran-
scriptome microarray studies of adrenal cancer [16–19].
This dataset is composed of 3 diﬀerent biological condi-
tions: (i) adrenal cortex carcinoma (ACC), 33 samples (ii)
adrenal cortex adenoma (ACA), 22 samples and (iii) nor-
mal adrenal cortex (NAC) that serves as control, 10 sam-
ples [18]. The insulin-like growth factor (IGF) signaling
system was identiﬁed as being one of the most dominantly
altered in ACC in the form of greatly increased expression
of IGF2 [17]. In a subsequent study [18], 10 genes associ-
ated with the cancer phenotype are identiﬁed. Steroid sig-
naling is associated with ACA since the activation of this
pathway is needed for diﬀerent hormone production. We
estimate the evolution of the values for Q0 and QA as we
vary the fold-change parameter fC0 and fCA , respectively.
For example, considering the diﬀerences between ACC
and NAC (i.e., the malignancy proﬁle), we computed sev-
eral subtraction proﬁles as displayed for Q0 (Figure 3D)
and QA (Figure 3E). As expected, Q0 is more restrictive
as fC0 increases and conversely when we increase fCA the
value of QA is more permissive. The results obtained here
for diﬀerentially expressed genes is presented in Figure 4.
A summary of the number of diﬀerentially expressed genes
is displayed in a Venn Diagram (Figure 4A). The advan-
tage of our method is that we can extend our scope by
looking at cases other than simply diﬀerential expression
amongst the diﬀerent biological conditions. For instance,
we can consider similar expression in one of the compari-
sons (Figure 4B) or even in two of them (Figure 4C). Each
of these possibilities give us diﬀerent insights. Among the
114 genes diﬀerentially detected, the collagen type I – alpha
1 gene (COL1A1) has been identiﬁed as present in the adre-
nal cancer malignancy (Figure 4D). In particular, we
detected the gene encoding secreted phosphoprotein 1
(SPP1), which is present in carcinoma and control samples,
with little variation while displaying a large variability in
the adenoma conditions. This can be explained since this
dataset has adenomas that produce diﬀerent hormones all
synthesized from cholesterol (steroids), which contribute
to the variability of this gene (Figure 4E). We can predict
that gene Interleukin-1 alpha (IL-1a) is similarly expressed
among carcinoma samples but is not relevant as a malig-
nancy marker since the expression is not statistically consis-
tent with the other two biological conditions (Figure 4F).
Variance estimation
The CDS statistical test described here is based on the
assumption of known variances of the signals. This
A B C
D
E
Figure 3 Test behavior validation
In silico simulations using standard normal distributed data with parameters x1, x2, r1, r2 capture 3 diﬀerent situations shown in A–C. A. Case of
diﬀerentially expressed gene having a signiﬁcant Q0 value ðQ0 < 0:05Þ but an high QA value. B. The opposite case being statistically similar ðQA < 0:05Þ. C.
Case where neither Q0 nor QA display statistical signiﬁcance. Our method is tested on a real biological dataset (panels D and E) showing the correct
behavior. D. Values of Q0 are directly changing as a function of the fC0 parameter. As we increase the fC0 parameter, the values of Q0 are higher. This
means that the more we increase the fC0 parameter the lessQ0 values we have for a given bin of the Q0 histogram. E. Values of QA are inversely changing as
a function of the fCA parameter. As we increase the fCA parameter the values of QA are lower. This means that the more we increase the fCA parameter the
more QA values we have for a given bin of the QA histogram.
132 Genomics Proteomics Bioinformatics 10 (2012) 127–135assumption is reasonable in cases where the technology
itself provides direct estimates of the variance as is the case
for dPCR and certain NGS applications using recall chem-istry. Furthermore, modern microarray platforms provide
coeﬃcient of variation estimates which can be used as
proxies for variance [20]. Another most important case is
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Figure 4 Experimental validation of our CDS statistical test
Venn Diagrams of the diﬀerentially expressed genes when comparing 3 diﬀerent biological conditions are shown in panel A–C. A. Comparing diﬀerential
expression across the three comparisons is the usual case. With the CDS method we can capture more cases, for instance shown in panel B and C.
B. Comparing diﬀerential expression in two subtractions and similarity in one subtraction. C. Comparing one diﬀerential expression and two similarity
expressions. Panels D–F. Examples of genes detected using both Q0 and QA values issued from our method. D. Diﬀerence in the three biological
conditions. E. Similarity between two biological conditions. F. Similarity in two comparisons and diﬀerence among the three biological conditions.
Tchitchek N et al / Statistical Test to Identify Distinctness and Similarity Concomitantly 133the often encountered scenario of biomedical investigations
where a large number of individual measurements are
available (e.g., a single recording per patient or subject).
Computing the biological variations from the entire cohort
of samples can then allow us to compare individual mea-
surements amongst each other with the CDS statistical test.
Multiple testing
The CDS statistical test can and should be combined with
false-positive discovery rates or similar corrections when
used in a serial manner. We have used successfully both
FDR and pFDR methods [21,22]. Note, that the data pre-
sented here were not subjected to multiple testing correc-
tion as they only serve to demonstrate the applicability of
the CDS method.
Conclusion
The CDS statistical test is suitable for quantitatively check-
ing statements, typically to determine conﬁdence intervals,
about the fold-change between the means of two normally
distributed variables, under assumptions that the variances
are known. Applied to the identiﬁcation of diﬀerentially
and similarly expressed genes in the context of microarray
measurements, this statistical test correctly identiﬁed genes
of interest in benchmark situations and also gave conﬁ-
dence intervals of the fold-change. Moreover, this statisti-cal test can be used for any -omics data as long as the
similarity or distinctness between two signals is measured
by the fold-change and the required assumptions are ful-
ﬁlled. Even if in the present case, assumptions have been
made that gene expression measurements are distributed
according to normal distributions with known variances,
the principle of the test remains valid for other distribu-
tions and it can be numerically implemented. Indeed,
Monte Carlo simulations can be performed to estimated
probabilities Prob ðY 1; Y 2Þ 2 cR0 bh0 ; bx1 ; bx2   and
Prob ðY 1; Y 2Þ 2 cRA chA ; bx1 ; bx2   when explicit forms can-
not be obtained easily. Finally, when variances of the nor-
mal distributions are not supposed to be known but have
to be estimated from the samples, Student t-distributions
can be used instead of the normal distributions.Methods
Explicit forms of probabilities
The explicit forms Prob ðY 1; Y 2Þ 2 cR0 bh0 ; bx1 ; bx2 jx1; x2 
and Prob ðY 1; Y 2Þ 2 cRA chA ; bx1 ; bx2 jx1; x2  have been
obtained by applying aﬃne transformations to the bivari-
ate normal distribution ðY 1; Y 2Þ in order to make the inte-
gration region rectangular and then easily computable
134 Genomics Proteomics Bioinformatics 10 (2012) 127–135using the standard bivariate normal complementary cumu-
lative distribution function. These explicit forms are given
in Supplementary materials (http://cds.ihes.fr) in Eqs. (5)
and (6).
Type I and type II risks upper bounds computation
It is notable that supremums of Eqs. (3) and (4) are reached
on boundaries of regions R0ðh0Þ and RAðhAÞ, meaning on
lines y ¼ arctan p
4
þ h0
 	
and y ¼ arctan p
4
 h0
 	
for Q0,
and on lines y ¼ arctan p
4
þ hA
 	
and y ¼ arctan p
4
 hA
 	
for QA. Albeit mathematically deﬁned, as in (3) and (4),
the computation of these probabilities begged for a numer-
ical estimation given the complexity of the explicit form of
their ﬁrst and second derivatives. In this line of thought, we
use numerical methods to obtain the maximum values of
the probabilities considering a ﬁnite number of instances
of the probability distribution functions (as opposed to
the exact functions from the mathematical deﬁnition) and
we evaluated them over a ﬁnite interval in the parameter
space (as opposed to the inﬁnite interval assumed in the
mathematical deﬁnition).
Conﬁdence interval computation
As Q0 increases (respectively QA increase) with h0 (resp.
hA), this delineation can done by performing a binary
search of the angle h0 (resp. hA) from
h^ ¼ arctan bx2bx1
 
 p
4
  to 0 (resp. to p4) until Q0 R0ðh0Þ;cR0bh0 ; x^1; x^2 Þ ¼ a (resp. QA RAðhAÞ;cRA chA ; bx1 ; bx2   ¼ a) is
reached.
Implementation
This statistical test has been implemented in Java and it is
possible to compute Q0 R0ðh0Þ;cR0 bh0 ; bx1 ; bx2   and
QA RAðhAÞ;cRA chA ; bx1 ; bx2   as well as the conﬁdence inter-
vals for a set of 30,000 values in a few minutes. The com-
putational speed allows us to imagine using this test for
the analysis of NGS data. It may be interesting to notice
here that some thought can be stated regarding the nature
of the distributions to be used for the analysis of NGS.
Indeed, in contrast to data from microarrays where the val-
ues are continuous signals, the measured values are dis-
crete, and thus the use of discrete distributions like the
negative binomial distribution can be interesting for better
modeling of assumptions. An R implementation of the
CDS statistical test is available at http://cds.ihes.fr.
Data processing
The transcriptome data discussed have ﬁrst been published
in [17], and are available from GEO [23] under Accession
No. GSE10927, and mace (http://www.mace.ihes.fr) underAccession No. 2651913582. Data were log-transformed,
subjected to an additional round of quality control
[24,25], and normalized using NeONORM [26] for subtrac-
tion proﬁling. No multiple testing correction was per-
formed so as to retain the original P values.
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